Archives of Dermatological Research

, Volume 305, Issue 3, pp 205–214 | Cite as

Photodynamic therapy: an innovative approach to the treatment of keloid disease evaluated using subjective and objective non-invasive tools

  • Sara Ud-Din
  • Grace Thomas
  • Julie Morris
  • Ardeshir Bayat
Original Paper


Optimal management for keloid disease (KD) is ill defined, with surgical excision resulting in recurrence rates over 50 %. Photodynamic therapy (PDT) uses light to activate a photosensitiser localised in diseased tissues. Two recent case studies and in vitro studies on keloid-derived fibroblasts indicate potential use of PDT in treating KD. Therefore, we hypothesized that there may be a role for PDT in the treatment of KD. Twenty KD patients were divided into three groups; existing keloid scar, post-surgical debulking and post-total surgical excision. Patients underwent three treatments of PDT at weekly intervals. Methyl aminolevulinate photosensitiser applied 3 h prior to PDT, administered at 37 J/cm2. Non-invasive measures provided quantitative data for pliability, haemoglobin, melanin, collagen and flux. Pain and pruritus scores were measured and patients’ were monitored for KD recurrence. All patients had reduced pain and pruritus scores. Haemoglobin flux (p = 0.032), collagen (p = 0.066) and haemoglobin levels (p = 0.060) decreased from week 1 to 3 in all except one patient where measurements were taken and pliability increased significantly (p = 0.001). Increases in pliability were significantly related to decreases in flux (p = 0.001). Only one patient with a keloid in a stress-prone anatomical location experienced recurrence of KD. All other patients had no recurrence at 9-month follow-up. Minimal side effects were reported. In conclusion, PDT reduces scar formation in KD evidenced by decreased blood flow, increased pliability, decreased collagen and haemoglobin levels. These findings indicate potential utility of PDT in the treatment of KD.


Keloid disease Photodynamic therapy Scar treatments Field therapy Methyl aminolevulinic acid 



5-Aminolevulinic acid


Adenosine 5-triphosphate


Full-field laser perfusion imaging

IL-1 alpha

Interleukin-1 alpha


Keloid disease


Methyl aminolevulinic acid


Matrix metalloproteinase


Photodynamic therapy


Protoporphyrin 9


Spectrophotometric intracutaneous analysis


Tumour necrosis factor-alpha

Supplementary material

403_2012_1295_MOESM1_ESM.pdf (183 kb)
Supplementary material 1 (PDF 183 kb)
403_2012_1295_MOESM2_ESM.pdf (172 kb)
Supplementary material 2 (PDF 171 kb)
403_2012_1295_MOESM3_ESM.pdf (241 kb)
Supplementary material 3 (PDF 240 kb)


  1. 1.
    Aarabi S, Bhatt K, Shi Y, Paterno J, Chang E, Loh S, Holmes J, Longaker M, Yee H, Gurtner G (2007) Mechanical load initiates hypertrophic scar formation through decreased cellular apoptosis. FASEB 21:3250–3261CrossRefGoogle Scholar
  2. 2.
    Akaishi S, Ogawa R, Hyakusoku H (2008) Keloid and hypertrophic scar: neurogenic inflammation hypotheses. Med Hypotheses 71:32–38PubMedCrossRefGoogle Scholar
  3. 3.
    Atilli SK, Lesar A, Mcneill A, Camacho-Lopez M, Moseley H, Ibbotson S, Samuel ID, Ferguson J (2009) An open pilot study of ambulatory photodynamic therapy using a wearable low-irradiance organic light-emitting diode light source in the treatment of nonmelanoma skin cancer. BJD 161:170–173CrossRefGoogle Scholar
  4. 4.
    Bayat A, Arscott G, Ollier W, Ferguson MWJ, McGrouther DA (2003) ‘Aggressive keloid’: a severe variant of familial keloid scarring. J R Soc Med 96:554–555PubMedCrossRefGoogle Scholar
  5. 5.
    Bock O, Schmid-Ott G, Malewski P, Mrowietz U (2006) Quality of life with keloid and hypertrophic scarring. Arch Derm Res 297:433–443PubMedCrossRefGoogle Scholar
  6. 6.
    Boehncke WH (2000) Systemic photodynamic therapy is a safe and effective treatment for psoriasis. Arch Dermatol 136:271–272PubMedCrossRefGoogle Scholar
  7. 7.
    Braakhuis BJM, Tabor MP, Kummer A, Leemans CR, Brakenhoff RH (2003) A genetic explanation of slaughter’s concept of field cancerization: evidence and clinical implications. Cancer Res 63:1727–1730PubMedGoogle Scholar
  8. 8.
    Braathen LR, Szeimies RM, Basset-Seguin N, Bissonnette R, Foley P, Pariser D, Roelandts R, Wennberg AM, Morton CA (2005) Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology. J Am Acad Dermatol 56:125–143CrossRefGoogle Scholar
  9. 9.
    Brown BC, McKenna SP, Siddhi K, McGrouther DA, Bayat A (2008) The hidden cost of skin scars: quality of life after skin scarring. J Plast Reconstr Aesthet Surg 61:1049–1058PubMedCrossRefGoogle Scholar
  10. 10.
    Brown B, McKenna S, Solomon M, Wilburn J, McGrouther DA, Bayat A (2010) The patient-reported impact of scars measure: development and validation. Plast Reconstr Surg 125:1439–1449PubMedCrossRefGoogle Scholar
  11. 11.
    Brown BC, Moss TP, McGrouther DA, Bayat A (2010) Skin scar preconceptions must be challenged: importance of self-perception in skin scarring. J Plast Reconstr Aesthet Surg 63:1022–1029PubMedCrossRefGoogle Scholar
  12. 12.
    Bruscino N, Lotti T, Rossi R (2011) Photodynamic therapy for a hypertrophic scarring: a promising choice. Photodermatol Photoimmunol Photomed 27:334–335PubMedCrossRefGoogle Scholar
  13. 13.
    Calzavara-Pinton PG, Venturini M, Sala R (2007) Photodynamic therapy: update 2006 Part 1: photochemistry and photobiology. JEADV 21:293–302PubMedGoogle Scholar
  14. 14.
    Campbell SM, Tyrrell J, Marshall R, Curnow A (2010) Effect of MAL-photodynamic therapy on hypertrophic scarring. Photodiagnosis Photodyn Ther 7:183–188PubMedCrossRefGoogle Scholar
  15. 15.
    Chiu LL, Sun CH, Yeh AT, Torkian B, Karamzadeh A, Tromberg B, Wong BJ (2005) Photodynamic therapy on keloid fibroblasts in tissue-engineered keratinocyte-fibroblast co-culture. Lasers Surg Med 37:231–244PubMedCrossRefGoogle Scholar
  16. 16.
    Christensen E, Warloe T, Kroon S, Funk J, Helsing P, Soler AM, Stang HJ, Vante O, Mork C (2010) Guidelines for practical use of MAL-PDT in non-melanoma skin cancer. JEADV 24:505–512PubMedGoogle Scholar
  17. 17.
    Dienus K, Bayat A, Gilmore BF, Seifert O (2010) Increased expression of fibroblast activation protein-alpha in keloid fibroblasts: implications for development of a novel treatment option. Arch Dermatol Res 302:725–731PubMedCrossRefGoogle Scholar
  18. 18.
    Durani P, Bayat A (2008) Levels of evidence for the treatment of keloid disease. J Plast Reconstr Aesthet Surg 61:4–17PubMedCrossRefGoogle Scholar
  19. 19.
    Froelich K, Staudenmaier R, Kleinsasser N, Hagen R (2007) Therapy of auricular keloids: a review of different treatment modalities and proposal for a therapeutic algorithm. Eur Arch Otorhino 264:1497–7508CrossRefGoogle Scholar
  20. 20.
    Gauglitz GG, Korting HC, Pavicic T, Ruzicka T, Jeschke MG (2011) Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. Mol Med 17:113–125PubMedCrossRefGoogle Scholar
  21. 21.
    Gulleth Y, Goldberg N, Silverman RP, Gastman BR (2010) What is the best surgical margin for a Basal cell carcinoma: a meta-analysis of the literature. Plast Reconstr Surg 126:1222–1231PubMedCrossRefGoogle Scholar
  22. 22.
    Halim AS, Emami A, Salahshourifar I, Kannan TP (2012) Keloid scarring: understanding the genetic basis, advances, and prospects. Arch Plast Surg 39:184–189PubMedCrossRefGoogle Scholar
  23. 23.
    Hollywood KA, Maatje M, Shadi IT, Henderson A, McGrouther DA (2010) Phenotypic profiling of keloid scars using FT-IR microspectroscopy reveals a unique spectral signature. Arch Dermatol Res 302:705–715PubMedCrossRefGoogle Scholar
  24. 24.
    Iqbal SA, Sidgwick GP, Bayat A (2012) Identification of fibrocytes from mesenchymal stem cells in keloid tissue: a potential source of abnormal fibroblasts in keloid scarring. Arch Dermatol Res 304:665–671PubMedCrossRefGoogle Scholar
  25. 25.
    Iqbal SA, Syed F, McGrouther DA, Paus R, Bayat A (2010) Differential distribution of haematopoietic and nonhaematopoietic progenitor cells in intralesional and extralesional keloid: do keloid scars provide a niche for nonhaematopoietic mesenchymal stem cells? Br J Dermatol 162:1377–1383PubMedCrossRefGoogle Scholar
  26. 26.
    Javad F, Day PJ (2012) Protein profiling of keloidal scar tissue. Arch Dermatol Res 304:533–540PubMedCrossRefGoogle Scholar
  27. 27.
    Karrer S, Abels C, Landthaler M, Szeimes RM (2000) Topical photodynamic therapy for localised scleroderma. Acta Derm Venereol 80:26–27PubMedCrossRefGoogle Scholar
  28. 28.
    Karrer S, Bosserhoff A, Weiderer P, Landthaler M, Szeimies RM (2003) Influence of 5-aminolevulinic acid and red light on collagen metabolism of human dermal fibroblasts. J Invest Dermatol 120:325–331PubMedCrossRefGoogle Scholar
  29. 29.
    Karrer S, Bosserhoff AK, Weiderer P, Landthaler M, Szeimies RM (2004) Keratinocyte-derived cytokines after photodynamic therapy and their paracrine induction of matrix metalloproteinases in fibroblasts. Br J of Derm 151:776–783CrossRefGoogle Scholar
  30. 30.
    King KM, McFetridge-Durdle J, LeBlanc P, Anzarut A, Tsuyuki RT (2008) A descriptive examination of the impact of sternal scar formation in women. Eur J Cardiovasc Nurs 8:112–118PubMedCrossRefGoogle Scholar
  31. 31.
    Lau K, Paus R, Tiede S, Day P, Bayat A (2009) Exploring the role of stem cells in cutaneous wound healing. Exp Dermatol 18:921–933PubMedCrossRefGoogle Scholar
  32. 32.
    Li X, Zhou ZP, Hu L, Zhang WJ, Li W (2012) Apoptotic cell death induced by 5-aminolevulinic acid-mediated photodynamic therapy of hypertrophic scar-derived fibroblasts. J Dermatolog Treat [Epub ahead of print]Google Scholar
  33. 33.
    Mendoza J, Sebastian A, Allan E, Allan D, Mandal P, Alonso-Rasgado T, Bayat A (2012) Differential cytotoxic response in keloid fibroblasts exposed to photodynamic therapy is dependent on photosensitiser precursor, fluence and location of fibroblasts within the lesion. Arch Dermatol Res 304:549–562Google Scholar
  34. 34.
    Mrowietz U, Seifert O (2009) Keloid scarring: new treatments ahead. Actas Dermosifiliogr 100:75–83PubMedCrossRefGoogle Scholar
  35. 35.
    Nie Z, Bayat A, Behzad F, Rhodes L (2010) Positive response of a recurrent keloid scar to topical methyl aminolevulinate-photodynamic therapy. Photodermatol Photoimmunol Photomed 26:330–332PubMedCrossRefGoogle Scholar
  36. 36.
    Peng Q, Soler AM, Warloe T, Nesland JM, Giercksky KE (2001) Selective distribution of porphyrins in skin thick basal cell carcinoma after topical application of methyl 5-aminolevulinate. J Photochem Photobiol B 62:140–145PubMedCrossRefGoogle Scholar
  37. 37.
    Seifert O, Mrowietz U (2009) Keloid Scarring: bench and bedside. Arch Dermatol Res 301:259–272PubMedCrossRefGoogle Scholar
  38. 38.
    Shih B, Bayat A (2012) Comparative genomic hybridisation analysis of keloid tissue in Caucasians suggests possible involvement of HLA-DRB5 in disease pathogenesis. Arch Dermatol Res 304:241–249PubMedCrossRefGoogle Scholar
  39. 39.
    Shih B, Bayat A (2010) Genetics of keloid scarring. Arch Dermatol Res 302:319–339PubMedCrossRefGoogle Scholar
  40. 40.
    Shih B, Garside E, McGrouther DA, Bayat A (2010) Molecular dissection of abnormal wound healing processes resulting in keloid disease. Wound Rep Regen 18:139–153CrossRefGoogle Scholar
  41. 41.
    Simon R, Eltze E, Scafer KL, Burger H, Semjonow A, Hertle L, Dokhorn-Dworniczak B, Terpe HJ, Bocker W (2001) Cytogenetic analysis of multifocal bladder cancer supports a monoclonal origin and intra epithelial spread of tumour cells. Cancer Res 61:332–355Google Scholar
  42. 42.
    Slaughter DP, Southwick HW, Smejkal W (1953) “Field cancerization” in oral stratified squamous epithelium. Cancer 6:963–968PubMedCrossRefGoogle Scholar
  43. 43.
    Syed F, Ahmadi E, Iqbal SA, Singh S, McGrouther DA, Bayat A (2010) Fibroblasts from the growing margin of keloid scars produce higher levels of collagen I and III expression compared to intra- and extra-lesional sites: clinical implications for lesional site-directed therapy. BJD 164:83–96CrossRefGoogle Scholar
  44. 44.
    Tabor MP, Brakenhoff RH, Ruijter-Scippers HJ, van der Wal JE, Snow GB, Leemans CR, Braakhuis BJM (2002) Multiple head and neck tumours frequently originate from a single preneoplastic lesion. Am J Pathol 161:1051–1060PubMedCrossRefGoogle Scholar
  45. 45.
    Tan K, Shah N, Pritchard S, McGrouther DA, Bayat A (2010) The influence of surgical excision margins on keloid prognosis. Ann Plas Surg 64:55–58CrossRefGoogle Scholar
  46. 46.
    Vincent AS, Phan TT, Mukhopadhyay A, Lim HY, Halliwell B, Wong KP (2008) Human skin keloid fibroblasts display bioenergetics of cancer cells. J Investig Dermatol 128:702–709PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Sara Ud-Din
    • 1
    • 2
  • Grace Thomas
    • 1
    • 2
  • Julie Morris
    • 3
  • Ardeshir Bayat
    • 1
    • 2
  1. 1.Faculty of Medical and Human Sciences, Institute of Inflammation and Repair, Manchester Academic Health Science CentreUniversity Hospital of South Manchester NHS Foundation Trust, University of ManchesterManchesterUK
  2. 2.Plastic and Reconstructive Surgery Research, Manchester Institute of BiotechnologyUniversity of ManchesterManchesterUK
  3. 3.Medical StatisticsUniversity Hospital of South Manchester NHS Foundation TrustManchesterUK

Personalised recommendations